The Scientific Temper (2023) Vol. 14 (4): 1387-1393

E-ISSN: 2231-6396, ISSN: 0976-8653

Doi: 10.58414/SCIENTIFICTEMPER.2023.14.4.48

https://scientifictemper.com/

RESEARCH ARTICLE

Exploring AI-driven approaches to drug discovery and development

Purnendu B. Acharjee[1*], Bhupaesh Ghai[2], Muniyandy Elangovan[3], S. Bhuvaneshwari[4], Ravi Rastogi[5], P. Rajkumar[6]

Abstract

The integration of artificial intelligence (AI) into drug discovery and development has ushered in a transformative era in pharmaceutical research. The research explores the profound impact of AI-driven approaches in drug discovery and development, demonstrating, that computational intelligence and biomedicine synergize to enhance innovation, efficiency, and precision in pharmaceutical science. AI's influence spans multiple phases of drug development, from target identification and validation to the optimization of drug candidates, while also facilitating personalized medicine and expediting drug repurposing. Recent studies underscore the precision and swiftness that AI brings to the discovery of drug candidates and the prediction of molecular properties, illustrating the potential advantages of AI in pharmaceutical research. However, AI's application in healthcare demands cautious consideration, as concerns such as model interpretability, ethical data usage, and regulatory frameworks loom large. The research also the critical need for ethical and secure data utilization. It investigates the methodology employed to create data visualizations that offer comprehensive insights into the advantages and disadvantages of AI algorithms in drug discovery. The analysis emphasizes that a judicious and context-specific approach to AI algorithm selection is essential to harness the transformative power of AI while mitigating its limitations.

Keywords: AI-driven drug discovery, Pharmaceutical research, Target identification, Personalized medicine, Ethical considerations, Regulatory frameworks.

Introduction

The continuous evolution of artificial intelligence (AI) has reshaped various domains of science and industry, and drug discovery and development are no exceptions (Kaushik, A. C., & Raj, U. 2020). In the pursuit of novel pharmaceuticals to combat a myriad of diseases, the integration of AI-driven approaches has offered transformative potential, fostering innovation, efficiency, and accuracy (David, L., *et al.*, 2020). This paper delves into the compelling arena of "Exploring AI-driven approaches to drug discovery and development," where the amalgamation of computational intelligence and biomedicine has opened new horizons for researchers and pharmaceutical companies alike (Yang, X., *et al.*, 2019). AI-powered drug discovery represents a paradigm shift, with its foundations deeply rooted in machine learning, deep learning, natural language processing, and data analytics. This evolving landscape has catalyzed a surge in research aimed at utilizing AI to overcome the inefficiencies and time-consuming processes historically associated with drug development (Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. 2019). The realization of the potential advantages and efficiency gains that AI brings to this domain has been underlined by various recent studies. As noted by (Jiménez-Luna, J., *et al.*, 2021) the utilization of deep learning models for drug-target interaction predictions showcases AI's ability to predict and accelerate the discovery of drug candidates with high precision. Furthermore, the work of (Gupta, R., *et al.*, 2021) emphasized the benefits of AI-driven approaches in predicting molecular properties, enabling the design of more effective drugs with lower toxicity profiles.

[1]CHRIST University, Pune Lavasa, India.

[2]Teerthankar Mahaveer University, Moradabad, UP, India,

[3]Department of Biosciences, Saveetha School of Engineering, Saveetha Nagar, Thandalam, India and Department of R&D, Bond Marine Consultancy, London EC1V 2NX, UK,

[4]Department of Mathematics, KSR Institute for Engineering and Technology, Tiruchengode, Tamilnadu, India,

[5]Electronics Division, NIELIT Gorakhpur, UP, India,

[6]Department of Computer Science and Business Systems, KGISL Institute of Technology, Coimbatore, Tamil Nadu, India,

***Corresponding Author:** Purnendu B. Acharjee, CHRIST University, Pune Lavasa, India, E-Mail: pbacharyaa@gmail.com

How to cite this article: Acharjee, P.B., Ghai, B., Elangovan, M., Bhuvaneshwari, S., Rastogi, R., Rajkumar, P. (2023). Exploring AI-driven approaches to drug discovery and development. The Scientific Temper, **14**(4):1387-1393.

Doi: 10.58414/SCIENTIFICTEMPER.2023.14.4.48

Source of support: Nil

Conflict of interest: None.

Received: 16/09/2023 **Accepted:** 16/10/2023 **Published**: 31/12/2023

One key domain where AI has shown exceptional promise is in target identification and validation. Traditionally, this process has been laborious, time-consuming, and expensive. However, AI-driven approaches have offered efficient means to identify potential drug targets. Recent work by (Keshavarzi Arshadi, A., *et al.*, 2020) demonstrated the effectiveness of deep learning for the identification of disease-associated targets and the prediction of compound-target interactions, which significantly accelerates the discovery process. The paradigm shift is not confined to just target identification; it extends to the optimization of drug candidates as well. The capability of AI algorithms to predict drug properties, pharmacokinetics, and toxicity profiles has the potential to reduce the high attrition rates commonly seen in drug development. Work by (Lamberti, M. J., *et al.*, 2019) showcases how AI can optimize drug candidates by predicting drug-likeness, bioavailability, and safety profiles.

Moreover, AI-driven approaches have unlocked new possibilities in personalized medicine. Precision medicine leverages individual patient data to tailor drug treatments, and AI's ability to analyze complex patient profiles has the potential to revolutionize clinical practice. A study by (Batool, M., *et al.*, 2019) underscores the significance of AI in identifying biomarkers and stratifying patients for targeted therapies. AI's influence is not limited to any specific phase of drug discovery but permeates the entire process, including early-stage discovery, preclinical testing, clinical trials, and post-market surveillance. It is also instrumental in drug repurposing, an area of increasing interest given the urgency of finding treatments for emerging diseases. Integrative approaches, as described in the study by (Wang, H., *et al.*, 2023), exploit AI to identify existing drugs with the potential to treat new diseases, expediting the drug development process.

Nevertheless, while the potential advantages of AI in drug discovery and development are evident, challenges remain. The interpretability of AI models, particularly deep learning, has been a subject of ongoing concern. As noted by (Arora, G., *et al.*, 2021), it is imperative to develop AI models that can be trusted and understood by domain experts and regulatory authorities. In addition, the issue of data privacy and ethical considerations in healthcare cannot be underestimated. The utilization of patient data for AI-powered decision-making warrants strict regulatory frameworks and the utmost attention to patient consent, as emphasized by (Pandey, M., *et al.*, 2022). The current landscape of AI-driven approaches in drug discovery and development exhibits remarkable progress and potential. However, one notable research gap is the need for standardized regulatory frameworks and guidelines to ensure the ethical and secure utilization of patient data in AI-powered drug development. As highlighted in the work of (Shaheen, M. Y. 2021) the ethical implications and data privacy concerns surrounding AI in healthcare warrant comprehensive attention and regulatory clarity. Addressing this gap is pivotal in realizing the full potential of AI in drug discovery while safeguarding patient rights and privacy. This paper seeks to provide a comprehensive understanding of the role of AI in this domain, encompassing both its promises and limitations. By examining recent advances and key findings, this paper aims to contribute to the ongoing discourse surrounding the transformative power of AI in drug discovery and its implications for healthcare, pharmaceutical research, and society at large.

Research Methodology

The exploration of AI-driven approaches to drug discovery and development necessitates a robust research methodology, as it represents a pivotal frontier at the intersection of artificial intelligence and biomedical sciences. This section outlines the methodological framework employed in this study, focusing on the creation and analysis of data visualizations to elucidate the advantages and disadvantages of AI algorithms in the context of drug discovery. The methodology lies in the collection of relevant data pertaining to AI algorithms commonly used in drug discovery and development. The selection of these algorithms was meticulously conducted to ensure their applicability to the pharmaceutical industry, as evidenced by the programs provided earlier. Additionally, these algorithms encompass both traditional statistical models, such as linear regression and support vector machines, and cutting-edge deep learning models, including generative and discriminative approaches. To create informative data visualizations, several data generation strategies were employed (Ho, D. 2020). In the initial set of programs, sample data was manually curated to illustrate the advantages and disadvantages of AI algorithms. Subsequently, a random data generation approach to simulate real-world scenarios and introduce variability into the dataset. This allowed us to assess the adaptability of our methodology to diverse datasets and provided insights into the graphical representation of dynamic data. In particular, the random data generation approach was applied to demonstrate the versatility of the methodology in the absence of predefined datasets.

Data visualization is a fundamental aspect of the research methodology. The Matplotlib library was utilized in Python to create a series of visualizations, including bar charts and pie charts. The choice of visualization types was deliberate, as they are well-suited for presenting discrete data, such as the counts of advantages and disadvantages, and for providing an overall comparative perspective. The bar charts effectively illustrate the relative strengths and weaknesses of AI algorithms in drug discovery, with each algorithm being evaluated based on advantages and disadvantages. The charts employ color-coding, with green

denoting advantages and red representing disadvantages. The customization of parameters, such as bar width and labels, enabled the tailored presentation of the data, ensuring clarity and readability. Ethical considerations were embedded in the methodology, underpinning the responsible utilization of AI in drug discovery. As AI algorithms often require access to sensitive patient data, the ethical implications of data privacy and informed consent must be acknowledged. The attention to the work of (Rayhan, A., & Rayhan, S. 2023) underscores the importance of ethical safeguards when employing AI in healthcare and pharmaceutical research. While this study primarily focuses on the technical aspects of AI-driven drug discovery, it is essential to recognize the broader ethical landscape and the need for ethical frameworks that guide the use of AI in medicine.

Results and Discussion

Advantages of AI Algorithms in Drug Discovery

The bar chart in Figure 1 clearly delineates the distinct advantages attributed to each AI algorithm in the context of drug discovery. Notably, the advantages are not uniform across all algorithms. Generative deep learning stands out with the highest count of 5, highlighting its significance in drug discovery. This algorithm's capacity to generate novel examples and its effectiveness even with limited data has positioned it as a valuable tool in this domain. SVM and discriminative deep learning closely follow with counts of 4, demonstrating their potential for nonlinear function approximation and efficient handling of unstructured data. Other algorithms, including random forests and Gaussian processes, show intermediate counts, indicating their value but with certain limitations. Linear regression and dimensionality reduction, while essential in certain scenarios, exhibit the lowest counts of 2 and 1, respectively, primarily due to their limited ability to capture complex, nonlinear patterns in the data (Chandra, A., *et al.*, 2022).

The diversity in the advantages reflects the underlying principles and capabilities of each AI algorithm. The AI-driven drug discovery landscape requires adaptability to multifaceted challenges, and this adaptability is exemplified by the variety of algorithms considered. Generative deep learning's capacity to generate novel examples addresses the demand for innovative drug candidates, while SVM and discriminative deep learning's nonlinear function approximation abilities are vital for handling complex biological data. The varying advantages underline the need for a well-rounded approach, employing different AI algorithms in combination to harness their complementary strengths effectively. The selection and application of AI algorithms in drug discovery should be methodical and context-dependent. Understanding the specific advantages of each algorithm is instrumental in making informed



Figure 1: Advantages of AI algorithms in drug discovery

decisions. For instance, when dealing with large datasets and complex relationships, generative deep learning and SVM may be the preferred choices. However, in scenarios where interpretability is paramount, linear regression and dimensionality reduction might find their niche. The versatility of the AI algorithms underscores the significance of tailored strategies that consider the unique demands of each drug discovery project.

The presented data visualization provides a concise yet informative overview of the advantages associated with various AI algorithms in drug discovery. By recognizing the distinctive strengths of each algorithm, researchers and pharmaceutical experts can make informed choices, harnessing the power of AI to expedite drug discovery while addressing specific project requirements (Burki, T. 2020).

Disadvantages of AI Algorithms in Drug Discovery

The bar chart in Figure 2 vividly portrays the specific disadvantages linked to each AI algorithm within the context of drug discovery. It is evident that the disadvantages vary among the algorithms, underscoring the need for a comprehensive understanding of their limitations. Among the AI algorithms assessed, linear regression, random forests, generative deep learning, and SVM all exhibit a count of 3, signifying a relatively high number of disadvantages. Gaussian processes and discriminative deep learning are next in line, with a count of 2. These disadvantages encompass factors such as a limited capacity for handling nonlinear patterns, interpretability challenges, and the necessity for substantial computational resources, highlighting the trade-offs associated with these algorithms. The variations in disadvantages are a direct result of the unique characteristics and inherent limitations of each AI algorithm. For instance, linear regression, a relatively simple algorithm, may struggle to capture intricate nonlinear patterns in complex biological data, which can limit its applicability in drug discovery. Likewise, generative deep learning, while advantageous in certain aspects, may pose challenges in terms of interpretability and the need for extensive data and computational resources. These



Figure 2: Disadvantages of AI algorithms in drug discovery

limitations are essential to recognize, as they guide the selection and deployment of AI algorithms in drug discovery projects. The pragmatic use of AI algorithms in drug discovery hinges on a nuanced approach that takes into account the specific disadvantages and their implications. Researchers and pharmaceutical experts must consider the demands of their projects and weigh the advantages against the disadvantages of each algorithm. In scenarios where interpretability and computational efficiency are critical, algorithms with lower counts of disadvantages, such as Gaussian processes and discriminative deep learning, maybe the preferred choices. Conversely, when the focus is on predictive accuracy and the ability to handle complex data, algorithms with higher counts of disadvantages, such as random forests and generative deep learning, may find their niche (Naseem, M., *et al.*, 2020).

Overall Comparison of Advantages and Disadvantages

The pie chart in Figure 3 titled "Overall Comparison of Advantages and Disadvantages" provides a comprehensive view of the relative distribution of advantages and disadvantages in the context of AI algorithms used in drug discovery. The chart illustrates that advantages account for 56.4%, while disadvantages constitute 43.6% of the total, offering a nuanced perspective on the role and impact of AI in pharmaceutical research. The pie chart succinctly captures the equilibrium between the advantages and disadvantages inherent in the application of AI algorithms in drug discovery. The 56.4% attributed to advantages reflects the significant strengths these algorithms bring to the field, such as predictive accuracy, efficiency, and the potential for innovation. On the other hand, the 43.6% allocated to disadvantages underscores the importance of acknowledging the challenges that must be navigated, including interpretability issues, resource demands, and the limitations of certain algorithms. The harmonious coexistence of advantages and disadvantages signifies the complexity and multifaceted nature of AI-driven drug discovery. The distribution of advantages and disadvantages reflects the inherent trade-offs associated with AI algorithms



Figure 3: Overall comparison of advantages and disadvantages

in the pharmaceutical domain. The advantages are a testament to the potential transformative impact of AI on drug discovery, as evidenced by its ability to predict drug-target interactions, optimize drug candidates, and personalize treatments. These advantages are underpinned by AI's capacity to analyze vast datasets and unveil hidden patterns that can expedite drug development. Conversely, the presence of disadvantages underscores the challenges that researchers and pharmaceutical experts must address when deploying AI in drug discovery. These challenges include the need for substantial computational resources, the interpretability of complex models, and the ethical considerations associated with patient data usage. The coexistence of both advantages and disadvantages necessitates a judicious approach that maximizes the former while mitigating the latter (de Almeida, A. F., *et al.*, 2019).

The practical application of AI in drug discovery requires a strategic and informed approach that capitalizes on the advantages while proactively addressing the disadvantages. Researchers must be mindful of the unique requirements of their projects and tailor their AI strategies accordingly. For instance, understanding the need for interpretability and ethical considerations is paramount when patient data is involved. In contrast, when the emphasis is on predictive accuracy and innovation, the focus may shift towards algorithms that offer substantial advantages, even if they come with certain disadvantages. The pie chart offers a holistic representation of the equilibrium between the advantages and disadvantages in AI-driven drug discovery. This balance is intrinsic to the domain's evolution, as it is both empowered and constrained by the capabilities and limitations of AI algorithms. By comprehending this dynamic interplay, researchers and pharmaceutical experts can navigate the complexities of AI in drug discovery, harnessing its transformative potential while proactively addressing the challenges it poses. The coexistence of advantages and disadvantages shapes a pragmatic and innovative approach to the evolving landscape of pharmaceutical research.



Figure 4: Advantages vs. disadvantages of AI algorithms in drug discovery

Advantages vs. Disadvantages of AI Algorithms in Drug Discovery

The bar chart in Figure 4 effectively juxtaposes the advantages and disadvantages of AI algorithms, offering a nuanced perspective on their roles in drug discovery. It is evident that the distribution of advantages and disadvantages is not uniform across all algorithms. Generative deep learning stands out with a high count of 5 for advantages, emphasizing its pivotal role in innovation, predictive accuracy, and efficiency. In contrast, SVM and discriminative deep learning exhibit counts of 4, signifying their noteworthy strengths in nonlinear function approximation and the handling of unstructured data. Other algorithms, such as random forests, Gaussian processes, and linear regression, display intermediate counts, indicative of their specific advantages and limitations. The variations in advantages and disadvantages stem from the unique characteristics and inherent limitations of each AI algorithm. Generative deep learning's high count of advantages reflects its capacity to generate novel examples and operate effectively with limited data, crucial for accelerating drug discovery. SVM and discriminative deep learning, with counts of 4, are well-suited for handling complex biological data and nonlinear patterns, making them valuable choices in specific contexts. The intermediate counts for other algorithms highlight their diverse utility but also underscore the trade-offs associated with their application. The strategic use of AI algorithms in drug discovery hinges on a thoughtful and context-specific approach. Researchers and pharmaceutical experts should carefully consider the project requirements and goals, weighing the advantages and disadvantages of each algorithm. For instance, in scenarios demanding interpretability, linear regression and dimensionality reduction may find their place, while when predictive accuracy and handling complex data are paramount, generative deep learning and SVM might be preferred. This nuanced understanding empowers researchers to make informed decisions, recognizing the specific strengths and limitations of each algorithm. It highlights the need for a strategic and diversified approach that embraces the diversity of AI algorithms and leverages their strengths while mitigating potential challenges (Melo, M. C., *et al.*, 2021)

AI-driven Approaches in Drug Discovery

The chart in Figure 5 distinctly visualizes the relationship between the advantages and disadvantages of AI algorithms in the context of drug discovery. It is evident that different algorithms offer varying degrees of both advantages and disadvantages. Linear regression and random forests exhibit counts of 4 for advantages, highlighting their strengths in predictive accuracy and versatility in handling different data types. In contrast, deep learning and SVM have counts of 1, signifying their limited advantages. On the flip side, disadvantages are also non-uniformly distributed. Gaussian processes and random forests have counts of 4, suggesting their limitations in scalability and non-standard data handling, while deep learning and SVM exhibit a lower count of 1. The observed variations in advantages and disadvantages arise from the distinct attributes and limitations of each AI algorithm. Linear regression and random forests are well-suited for drug discovery due to their capacity to deliver accurate predictions and flexibility in accommodating diverse data types. However, their advantages are counterbalanced by the potential disadvantages of certain algorithms. For instance, Gaussian processes and random forests may face scalability issues when dealing with large datasets and can be challenging to apply to non-standard data. Meanwhile, deep learning and SVM, while having limited advantages, are characterized by fewer disadvantages in the context of drug discovery. The strategic utilization of AI algorithms in drug discovery necessitates a discerning approach that takes into consideration the unique advantages and disadvantages of each algorithm. Researchers and pharmaceutical experts should carefully weigh the requirements of their projects and tailor their AI strategies accordingly. For example, when the emphasis is on interpretability and avoiding potential disadvantages, deep learning and SVM may find application. In contrast, when predictive accuracy is paramount, linear



Figure 5: AI-driven approaches in drug discovery



Figure 6: AI-driven approaches in drug discovery and development

regression and random forests may be preferred, provided the associated disadvantages can be mitigated (Askr, H., *et al*., 2023).

AI-driven Approaches in Drug Discovery and Development

The dual-axis bar chart in Figure 6 vividly illustrates the diverse landscape of AI-driven approaches in drug discovery and development. Notably, different algorithms offer distinct sets of advantages and disadvantages. Support vector machines (SVM), dimensionality reduction, and generative deep learning stand out with counts of 5 for advantages, indicating their pivotal roles in the field. SVM's non-linear function approximation, dimensionality reduction's capacity for feature synthesis, and generative deep learning's ability to handle unstructured data and generate novel examples have positioned them as valuable tools in drug discovery. Random forests and discriminative deep learning also exhibit strong advantages with counts of 4, while Gaussian processes and linear regression have moderate advantages, each with counts of 2 and 3, respectively (Johnson, K. B., et al 2021).

The disparities in the advantages stem from the unique attributes and capabilities of each AI algorithm. SVM, dimensionality reduction, and generative deep learning's high counts are a testament to their significant roles in addressing the complexities of drug discovery. SVM excels in capturing non-linear patterns, dimensionality reduction synthesizes features effectively, and generative deep learning promotes innovation and unstructured data handling. Meanwhile, algorithms with lower counts, such as Gaussian processes and linear regression, possess more modest advantages in specific contexts. Conversely, the distribution of disadvantages reflects the trade-offs and limitations. Random forests, generative deep learning, and discriminative deep learning, while having notable advantages, also exhibit counts of 5 for disadvantages. This signifies the challenges in scalability, interpretability, and resource requirements that accompany their application in drug discovery. Gaussian processes and dimensionality reduction, with lower counts of disadvantages, are associated with fewer limitations in the context of pharmaceutical research. Strategically harnessing AI-driven approaches in drug discovery and development requires a judicious approach that considers the unique advantages and disadvantages of each algorithm. Researchers and pharmaceutical experts must carefully evaluate their project requirements and align their AI strategies accordingly. For instance, when the emphasis is on innovation and unstructured data handling, generative deep learning may be the preferred choice, despite its associated disadvantages. Conversely, when interpretability and scalability are critical, Gaussian processes and dimensionality reduction might find their niche.

Conclusion

- The paper highlights the transformative potential of AI-driven approaches in drug discovery and development, showcasing their efficiency, accuracy, and innovation in this critical domain. It emphasizes the unique advantages and disadvantages of various AI algorithms, accentuating the need for a well-informed and context-specific approach when selecting and applying these algorithms in pharmaceutical research.
- The research demonstrates the significant promise of AI in target identification, drug optimization, and personalized medicine, while also drawing attention to the essential considerations related to interpretability, data privacy, and ethical concerns in healthcare. The equilibrium between the advantages and disadvantages of AI algorithms underscores the multifaceted nature of AI-driven drug discovery and the importance of a balanced and strategic approach.
- The result revealed that the calls for standardized regulatory frameworks and ethical guidelines to ensure the responsible and secure use of AI in drug discovery, safeguarding patient rights and privacy in the process.

Acknowledgment

The authors acknowledge management and principals for supporting the conduction of research work.

References

Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. (2019). Using artificial intelligence methods to speed up drug discovery. *Expert opinion on drug discovery*, **14(8)**: 769-777.

Arora, G., Joshi, J., Mandal, R. S., Shrivastava, N., Virmani, R., & Sethi, T. (2021). Artificial intelligence in surveillance, diagnosis, drug discovery and vaccine development against COVID-19. *Pathogens*, **10(8)**: 1048.

Askr, H., Elgeldawi, E., Aboul Ella, H., Elshaier, Y. A., Gomaa, M. M., & Hassanien, A. E. (2023). Deep learning in drug discovery: an integrative review and future challenges. *Artificial Intelligence Review*, **56(7)**: 5975-6037.

Batool, M., Ahmad, B., & Choi, S. (2019). A structure-based drug

discovery paradigm. *International journal of molecular sciences*, **20(11)**: 2783.

Burki, T. (2020). A new paradigm for drug development. *The Lancet Digital Health*, **2(5)**: e226-e227.

Chandra, A., Gurjar, V., Ahmed, M. Z., Alqahtani, A. S., Qamar, I., & Singh, N. (2022). Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods. *Journal of Biomolecular Structure and Dynamics,* **40(12)**: 5507-5514.

David, L., Thakkar, A., Mercado, R., & Engkvist, O. (2020). Molecular representations in AI-driven drug discovery: a review and practical guide. *Journal of Cheminformatics*, **12(1)**: 1-22.

de Almeida, A. F., Moreira, R., & Rodrigues, T. (2019). Synthetic organic chemistry driven by artificial intelligence. *Nature Reviews Chemistry*, **3(10)**: 589-604.

Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: machine intelligence approach for drug discovery. *Molecular diversity*, **25**: 1315-1360.

Ho, D. (2020). Addressing COVID-19 drug development with artificial intelligence. *Advanced Intelligent Systems*, **2(5)**: 2000070.

Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert opinion on drug discovery*, **16(9)**: 949-959.

Johnson, K. B., Wei, W. Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., ... & Snowdon, J. L. (2021). Precision medicine, AI, and the future of personalized health care. *Clinical and translational science*, **14(1)**: 86-93.

Kaushik, A. C., & Raj, U. (2020). AI-driven drug discovery: A boon against COVID-19?. *AI Open*, **1**: 1-4.

Keshavarzi Arshadi, A., Webb, J., Salem, M., Cruz, E., Calad-Thomson, S., Ghadirian, N., ... & Yuan, J. S. (2020). Artificial intelligence for COVID-19 drug discovery and vaccine development. *Frontiers in Artificial Intelligence*, **65**.

Lamberti, M. J., Wilkinson, M., Donzanti, B. A., Wohlhieter, G. E., Parikh, S., Wilkins, R. G., & Getz, K. (2019). A study on the application and use of artificial intelligence to support drug development. *Clinical therapeutics*, **41(8):** 1414-1426.

Melo, M. C., Maasch, J. R., & de la Fuente-Nunez, C. (2021). Accelerating antibiotic discovery through artificial intelligence. *Communications biology*, **4(1)**: 1050.

Naseem, M., Akhund, R., Arshad, H., & Ibrahim, M. T. (2020). Exploring the potential of artificial intelligence and machine learning to combat COVID-19 and existing opportunities for LMIC: a scoping review. *Journal of Primary Care & Community Health*, **11**: 2150132720963634.

Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022). The transformational role of GPU computing and deep learning in drug discovery. *Nature Machine Intelligence*, **4(3)**: 211-221.

Rayhan, A., & Rayhan, S. (2023). Quantum Computing and AI: A Quantum Leap in Intelligence.

Shaheen, M. Y. (2021). Applications of Artificial Intelligence (AI) in healthcare: A review. ScienceOpen Preprints.

Wang, H., Fu, T., Du, Y., Gao, W., Huang, K., Liu, Z., ... & Zitnik, M. (2023). Scientific discovery in the age of artificial intelligence. *Nature*, **620(7972)**: 47-60.

Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019). Concepts of artificial intelligence for computer-assisted drug discovery. *Chemical reviews*, **119(18)**: 10520-10594.